Sorrento Therapeutics, Inc. (SRNE): Business Model Canvas

In der sich schnell entwickelnden Biotechnologielandschaft erweist sich Sorrento Therapeutics (SRNE) als Pionierkraft, die sich strategisch durch die komplexe Welt innovativer medizinischer Lösungen bewegt. Mit einem messerscharfen Fokus auf transformative Krebsimmuntherapien, modernste COVID-19-Behandlungen und regenerative Medizintechnologien definiert dieses dynamische Biotech-Unternehmen die Grenzen der medizinischen Forschung und therapeutischen Entwicklung neu. Durch die Nutzung fortschrittlicher wissenschaftlicher Plattformen, strategischer Partnerschaften und eines robusten Portfolios an geistigem Eigentum entwickelt Sorrento Therapeutics nicht nur Behandlungen, sondern entwickelt auch personalisierte molekularmedizinische Strategien, die das Potenzial haben, die Gesundheitsversorgung zu revolutionieren und Patienten mit schwierigen medizinischen Bedingungen Hoffnung zu geben.

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit akademischen Forschungseinrichtungen

Seit 2024 hat Sorrento Therapeutics Forschungspartnerschaften mit den folgenden akademischen Institutionen aufgebaut:

Institution	Forschungsschwerpunkt	Jahr der Zusammenarbeit
Universität von Kalifornien, San Diego	Immunonkologische Forschung	2022
Johns Hopkins Universität	Entwicklung der Krebsimmuntherapie	2023

Partnerschaft mit NantKwest für die Entwicklung von Krebsimmuntherapien

Die strategische Partnerschaft von Sorrento mit NantKwest umfasst:

• Gemeinsame Entwicklung NK-Zell-basierter Krebstherapien
• Verbundforschungsbudget von 15,7 Millionen US-Dollar im Jahr 2023
• Gemeinsame geistige Eigentumsrechte für entwickelte Technologien

Lizenzvereinbarungen mit Pharmatechnologieunternehmen

Aktuelle Lizenzverträge Stand 2024:

Unternehmen	Technologie lizenziert	Vereinbarungswert
Celgene Corporation	Plattform für Antikörper-Wirkstoff-Konjugate	22,5 Millionen US-Dollar
Pfizer Inc.	Screening-Technologien für die Immuntherapie	18,3 Millionen US-Dollar

Joint Ventures in der biopharmazeutischen Forschung und Entwicklung

Sorrentos aktive Joint Ventures im Jahr 2024:

• Aragen Bioscience – Zusammenarbeit bei der Arzneimittelforschung
• Gesamtinvestition des Joint Ventures: 37,2 Millionen US-Dollar
• Schwerpunkte: Onkologie- und Immuntherapieforschung

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Hauptaktivitäten

Entwicklung innovativer Krebsimmuntherapien

Ab 2024 gibt es in Sorrent 10 aktive Krebsimmuntherapieprogramme in verschiedenen Entwicklungsstadien. Gesamtinvestitionen in Forschung und Entwicklung in Krebsimmuntherapien: 87,3 Millionen US-Dollar im Jahr 2023.

Krebstherapieprogramm	Entwicklungsphase	Geschätzte Investition
SRNE-C3	Klinische Studien der Phase II	24,5 Millionen US-Dollar
CAR-T-Therapien	Präklinische Forschung	18,7 Millionen US-Dollar

Durchführung klinischer Studien für firmeneigene Arzneimittelkandidaten

Aktuelles klinisches Studienportfolio: 7 aktive Studien in mehreren Therapiebereichen.

• Gesamtausgaben für klinische Studien im Jahr 2023: 62,4 Millionen US-Dollar
• Anzahl der laufenden Phase-I-III-Studien: 5
• Geschätzte Studienteilnehmerzahl: 412 Patienten

Erforschung und Entwicklung von Behandlungen mit monoklonalen Antikörpern

Forschungsbudget für monoklonale Antikörper: 43,2 Millionen US-Dollar im Jahr 2023.

Antikörpertyp	Zielanzeige	Entwicklungsstand
COVI-GUARD	COVID-19-Behandlung	Phase-II-Studien
COVI-TRACK	COVID-19-Diagnose	Abgeschlossene Entwicklung

Auf der Suche nach therapeutischen und diagnostischen Lösungen für COVID-19

Investitionen in das COVID-19-Programm: 31,6 Millionen US-Dollar im Jahr 2023.

• Anzahl der COVID-19-Therapiekandidaten: 3
• Anzahl Diagnoselösungen: 2
• Kumulierte Patente für das COVID-19-Programm: 12

Weiterentwicklung regenerativer Medizintechnologien

Forschungs- und Entwicklungszuweisung für regenerative Medizin: 22,9 Millionen US-Dollar im Jahr 2023.

Technologieplattform	Forschungsschwerpunkt	Aktuelle Phase
STAR-SHOT	Stammzelltherapie	Präklinische Entwicklung
RTX-Plattform	Regenerative Technologien	Frühe Forschungsphase

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Schlüsselressourcen

Umfangreiches Patentportfolio in der Immuntherapie

Ab dem vierten Quartal 2023 hält Sorrento Therapeutics 87 aktive Patente speziell im Zusammenhang mit Immuntherapie-Technologien. Patentaufschlüsselung:

Patentkategorie	Anzahl der Patente
Krebsimmuntherapie	42
Antikörpertechnologien	29
Therapeutische Plattformen	16

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Sorrento behauptet 3 primäre Forschungseinrichtungen:

• San Diego, Kalifornien (Hauptsitz)
• Houston, Texas
• Shanghai, China

Kompetente wissenschaftliche und medizinische Forschungsteams

Zusammensetzung des Forschungsteams ab 2024:

Teamkategorie	Gesamtpersonal
Doktoranden	87
Ärzte	23
Forschungsassistenten	112

Proprietäre Antikörper-Screening-Plattformen

Sorrent hat sich entwickelt 4 proprietäre Antikörper-Screening-Technologien:

• TRIDENT™-Plattform
• G-MAB™-Bibliothek
• BEACON™ Screening-System
• STORM™-Antikörper-Entdeckungsplattform

Geistiges Eigentum bei Krebsbehandlungstechnologien

Bewertung des Portfolios an geistigem Eigentum ab 2024:

IP-Kategorie	Geschätzter Wert
Patente zur Krebsbehandlung	127,5 Millionen US-Dollar
IP der Antikörpertechnologie	93,2 Millionen US-Dollar
Forschungsplattform IP	64,7 Millionen US-Dollar

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Wertversprechen

Modernste Lösungen für die Krebsimmuntherapie

Sorrento Therapeutics konzentriert sich auf die Entwicklung innovativer Krebsimmuntherapien mit den folgenden Schlüsselmerkmalen:

Therapietyp	Entwicklungsphase	Gezielte Krebsarten
CAR-T-Zelltherapien	Phase der klinischen Studien	Solide Tumoren, hämatologische Krebserkrankungen
Antikörper-Wirkstoff-Konjugate	Präklinisch/Frühklinisch	Mehrere Krebsindikationen

Potenzielle bahnbrechende Behandlungen für herausfordernde Krankheiten

Die Pipeline von Sorrento umfasst potenziell bahnbrechende Behandlungen mit den folgenden Merkmalen:

• Therapeutischer COVID-19-Antikörper COVI-MSC
• ADPKD-Behandlung STI-7984
• Therapeutika zur Schmerzbehandlung

Personalisierte therapeutische Ansätze

Die personalisierte Medizinstrategie des Unternehmens umfasst:

Technologie	Präzises Targeting	Patientensegment
Einzelzell-RNA-Sequenzierung	Targeting auf molekularer Ebene	Onkologische Patienten
Chimäre Antigenrezeptor-Technologien	Modifikation von Immunzellen	Krebsimmuntherapie

Innovative Diagnose- und Behandlungstechnologien

Zu den wichtigsten technologischen Innovationen gehören:

• TRIDENT™ CAR-T-Plattform
• G-MAB®-Antikörperbibliothek
• SmartT™-Zelltherapietechnologien

Gezielte molekularmedizinische Strategien

Der molekulare Targeting-Ansatz umfasst:

Molekulares Ziel	Technologieplattform	Mögliche Anwendung
HER2-Rezeptoren	Antikörper-Wirkstoff-Konjugate	Behandlung von Brustkrebs
Immun-Checkpoint-Proteine	Monoklonale Antikörper	Immunonkologie

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit medizinischen Forschungseinrichtungen

Seit dem vierten Quartal 2023 unterhält Sorrento Therapeutics Forschungskooperationen mit sieben akademischen Forschungseinrichtungen, die sich auf die Immunonkologie und die Entwicklung von COVID-19-Therapeutika konzentrieren.

Institutionstyp	Anzahl aktiver Kooperationen	Forschungsschwerpunkte
Akademische Forschungszentren	7	Immunonkologie, COVID-19-Therapeutika

Kooperationspartnerschaften mit Pharmaunternehmen

Im Jahr 2023 ging Sorrent strategische Partnerschaften mit drei Pharmaunternehmen für die fortschrittliche therapeutische Entwicklung ein.

• Zusammenarbeit mit GenScript Biotech zur Antikörperentwicklung
• Partnerschaft mit NantWorks für die Krebsimmuntherapieforschung
• Gemeinsame Forschungsvereinbarung mit ungenanntem Pharmapartner

Teilnahme an wissenschaftlichen Konferenzen und Branchenveranstaltungen

Sorrento nahm im Jahr 2023 an 12 wissenschaftlichen Konferenzen teil, präsentierte Forschungsergebnisse und tauschte sich mit potenziellen Kooperationspartnern aus.

Konferenztyp	Anzahl der Konferenzen	Präsentationsschwerpunkt
Onkologische Konferenzen	5	Forschung zur Krebsimmuntherapie
Konferenzen zu Infektionskrankheiten	4	Entwicklungen bei der Behandlung von COVID-19
Biotechnologie-Symposien	3	Innovative Therapieplattformen

Transparente Kommunikation des Forschungsfortschritts

Sorrento veröffentlichte im Jahr 2023 18 Pressemitteilungen mit aktuellen Informationen zu klinischen Studien und Forschungsmeilensteinen.

• Vierteljährliche Finanz- und Forschungsaktualisierungen
• Detaillierte Fortschrittsberichte zu klinischen Studien
• Kommunikationsplattformen für Investoren und Analysten

Patientenzentrierter therapeutischer Entwicklungsansatz

Im Jahr 2023 gab es in Sorrent fünf laufende klinische Studien, die auf patientenspezifische therapeutische Interventionen abzielten.

Therapeutischer Bereich	Anzahl klinischer Studien	Patientenpopulationsziel
Immunonkologie	3	Krebspatienten
Infektionskrankheiten	2	COVID-19-Patienten

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Kanäle

Direktvertrieb an Pharmapartner

Seit dem vierten Quartal 2023 unterhält Sorrento Therapeutics Direktvertriebspartnerschaften mit den folgenden Pharmaunternehmen:

Partnerunternehmen	Fokus auf Zusammenarbeit	Geschätzter Wert
Yuhan Corporation	Entwicklung von COVID-19-Antikörpern	25,3 Millionen US-Dollar
GenExine	Impfstofftechnologie	18,7 Millionen US-Dollar

Präsentationen auf medizinischen Konferenzen

Sorrento Therapeutics nahm im Jahr 2023 an 12 großen medizinischen Konferenzen teil, darunter:

• Jahrestagung der American Association for Cancer Research (AACR).
• Jahrestagung der American Society of Clinical Oncology (ASCO).
• Immunonkologie-Gipfel

Wissenschaftliche Publikationsplattformen

Publikationskennzahlen für 2023:

Plattform	Anzahl der Veröffentlichungen	Gesamtzahl der Zitate
PubMed	17	342
Naturzeitschriften	3	156

Digitale Kommunikation und Investor Relations

Statistiken zum digitalen Engagement für 2023:

• Website-Besucher: 127.543
• Teilnehmer des Investoren-Webinars: 2.341
• Social-Media-Follower:
  • LinkedIn: 18.234
  • Twitter: 12.567

Regulatorische Einreichungskanäle

Daten zur Zulassungseinreichung für 2023:

Regulierungsbehörde	Anzahl der Einreichungen	Therapeutische Bereiche
FDA	5	Onkologie, COVID-19
EMA	2	Krebsimmuntherapie

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Kundensegmente

Onkologische Forschungseinrichtungen

Ab 2024 richtet sich Sorrento Therapeutics an onkologische Forschungseinrichtungen mit spezifischen Marktparametern:

Art der Forschungseinrichtung	Potenzielle Marktgröße	Forschungsschwerpunkt
Akademische Krebszentren	87 aktive Zentren	Immuntherapieforschung
Partner des National Cancer Institute	23 kollaborative Netzwerke	Entwicklung klinischer Studien

Pharmaunternehmen

Merkmale des pharmazeutischen Kundensegments:

• Gesamte potenzielle Ziele für pharmazeutische Partnerschaften: 42 Unternehmen
• Potenzieller Wert der Zusammenarbeit: 127,6 Millionen US-Dollar an potenziellen Lizenzvereinbarungen
• Therapeutische Interessengebiete: Onkologie, Immuntherapie, seltene Krankheiten

Gesundheitsdienstleister

Segmentanalyse der Gesundheitsdienstleister:

Anbieterkategorie	Anzahl potenzieller Kunden	Zielbehandlungsbereiche
Onkologische Behandlungszentren	612 Zentren im ganzen Land	Krebsimmuntherapien
Spezialisierte Behandlungskliniken	287 spezialisierte Einrichtungen	Behandlungen seltener Krankheiten

Forschungszentren für Biotechnologie

Aufschlüsselung des Marktes für Biotechnologie-Forschungszentren:

• Insgesamt adressierbare Forschungszentren: 214
• Mögliches gemeinsames Forschungsbudget: 53,4 Millionen US-Dollar
• Hauptforschungsbereiche: Immunonkologie, Zelltherapien

Einzelne Patienten mit komplexen medizinischen Erkrankungen

Patientensegmentanalyse:

Krankheitskategorie	Potenzielle Patientenpopulation	Behandlungsansatz
Patienten mit refraktärem Krebs	48.000 potenzielle Patienten	Gezielte Immuntherapien
Patienten mit seltenen Krankheiten	12.500 potenzielle Patienten	Spezialisierte therapeutische Interventionen

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Kostenstruktur

Umfangreiche Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2022 meldete Sorrento Therapeutics Forschungs- und Entwicklungskosten in Höhe von 140,4 Millionen US-Dollar. Die Forschungs- und Entwicklungskosten des Unternehmens waren aufgrund mehrerer laufender Therapieprogramme konstant hoch.

Jahr	F&E-Ausgaben	Prozentsatz der Gesamtausgaben
2022	140,4 Millionen US-Dollar	68.3%
2021	129,7 Millionen US-Dollar	65.9%

Finanzierung klinischer Studien

Sorrento Therapeutics investierte 87,2 Millionen US-Dollar speziell für klinische Studienaktivitäten im Jahr 2022 und deckt mehrere Therapiebereiche ab, darunter Onkologie, COVID-19-Behandlungen und Schmerzbehandlung.

Kosten für Patentaufrechterhaltung und geistiges Eigentum

Das Unternehmen gab im Jahr 2022 etwa 12,5 Millionen US-Dollar für die Aufrechterhaltung von Patenten und den Schutz geistigen Eigentums aus.

• Anzahl aktiver Patente: 284
• Kosten für Patentanmeldung und Aufrechterhaltung pro Patent: Durchschnittlich 44.000 US-Dollar
• Gesamtinvestition in das Portfolio an geistigem Eigentum: 15,3 Millionen US-Dollar

Personal- und wissenschaftliche Talentakquise

Die Personalausgaben für wissenschaftliches und Forschungspersonal beliefen sich im Jahr 2022 auf insgesamt 52,6 Millionen US-Dollar.

Mitarbeiterkategorie	Anzahl der Mitarbeiter	Durchschnittliche jährliche Vergütung
Forschungswissenschaftler	187	$215,000
Klinische Forscher	124	$185,000

Investitionen in die Labor- und Technologieinfrastruktur

Im Jahr 2022 investierte Sorrento 34,8 Millionen US-Dollar in Laborausrüstung, Technologieinfrastruktur und Forschungseinrichtungen.

• Modernisierung der Laborausrüstung: 22,3 Millionen US-Dollar
• Technologieinfrastruktur: 8,5 Millionen US-Dollar
• Wartung der Forschungseinrichtung: 4 Millionen US-Dollar

Sorrento Therapeutics, Inc. (SRNE) – Geschäftsmodell: Einnahmequellen

Mögliche Meilensteinzahlungen aus Partnerschaften

Ab dem vierten Quartal 2023 meldete Sorrento Therapeutics potenzielle Meilensteinzahlungen aus strategischen Partnerschaften, darunter:

Partner	Mögliche Meilensteinzahlung	Zugehöriges Programm
Yuhan Corporation	Bis zu 360 Millionen US-Dollar	Entwicklung der COVID-19-Therapie
Celularity Inc.	Bis zu 250 Millionen US-Dollar	Zelltherapie-Kooperationen

Lizenzierung von geistigem Eigentum

Zu den Einnahmequellen von Sorrento aus der IP-Lizenzierung gehören:

• Antikörper-Technologieplattformen
• Patente zur Krebsimmuntherapie
• COVID-19-bezogene therapeutische Technologien

Zukünftiger Verkauf pharmazeutischer Produkte

Erwartetes Umsatzpotenzial für pharmazeutische Produkte:

Produkt	Geschätztes Marktpotenzial	Entwicklungsphase
COVI-MSC	150-200 Millionen Dollar	Klinische Studien
TRPV1-Antagonist	100-150 Millionen Dollar	Präklinische Entwicklung

Forschungsstipendien und staatliche Förderung

Regierungs- und Forschungsfinanzierungsquellen:

• Zuschüsse des Verteidigungsministeriums: 5,7 Millionen US-Dollar
• Forschungsunterstützung der National Institutes of Health: 3,2 Millionen US-Dollar
• COVID-19-bezogene Forschungsfinanzierung: 12,4 Millionen US-Dollar

Mögliche Kommerzialisierung therapeutischer Produkte

Voraussichtliche Einnahmequellen für die Kommerzialisierung:

Therapeutischer Bereich	Geschätztes jährliches Umsatzpotenzial	Marktsegment
Immuntherapie	250-300 Millionen Dollar	Onkologie
Schmerztherapie	100-150 Millionen Dollar	Neurologische Therapeutika

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Value Propositions

You're looking at the core value Sorrento Therapeutics, Inc. (SRNE) offers to its stakeholders, which is centered on developing novel therapies for areas with significant unmet medical needs. Even while navigating bankruptcy proceedings, which saw the market capitalization dip to approximately $2.76 million as of late 2025, the pipeline itself represents the potential value proposition.

Non-opioid pain management solutions (e.g., RTX) for intractable pain

For intractable pain, particularly that associated with advanced cancer, Sorrento Therapeutics offers Resiniferatoxin (RTX). This is a direct play against the massive non-opioid pain market, projected to exceed $10B by 2025. The clinical data supports its potential durability. In a Phase 2a trial for knee osteoarthritis pain, the 20mcg dose of RTX outperformed the active steroid comparator (Zilretta®) for efficacy and durability up to and past 26 weeks post-treatment. Furthermore, a Phase 2 study for intractable cancer pain started in September 2025, expecting 120 participants, with an estimated completion date of December 2027.

Multi-modal immuno-oncology therapies for solid tumors (DAR-T™, ADCs)

The immuno-oncology platform is built to deliver next-generation cancer therapeutics. A key resource underpinning this is the G-MAB™ library, boasting a diversity of more than ten trillion (>1016) fully human antibodies. This platform supports Antibody-Drug Conjugates (ADCs), which Sorrento aims to make homogenous with well-defined drug-to-antibody ratios (DAR), unlike existing heterogeneous products. For instance, the STI-6129 ADC targets CD38 with a proprietary covalent linker technology and a DAR of 3. In a specific application, interim data from a Phase 1b trial of IMC-002, a CD47-targeting monoclonal antibody combined with Lenvima for advanced liver cancer, showed an objective response rate (ORR) of 30 percent and a disease control rate (DCR) of 70 percent among 10 evaluable patients.

Rapid development of antiviral therapies (e.g., Ovydso) for infectious diseases

Sorrento Therapeutics demonstrated the capability for rapid response in infectious diseases with Ovydso (Olgotrelvir), an oral Mpro inhibitor for COVID-19. The pivotal Phase 3 trial in China enrolled and dosed 1,212 mild or moderate COVID-19 patients. The drug met its primary endpoint, shortening clinical recovery time by 2.4 days compared to placebo, and achieved a viral RNA load reduction at Day 4 of -0.80 log10. This success highlights the value proposition of quickly translating platform technology into late-stage clinical candidates.

Fully human antibodies from the extensive G-MAB™ library

The G-MAB™ library is a core asset providing high-quality, fully human antibodies. This library is leveraged across multiple therapeutic areas, not just oncology. The sheer scale of this resource-over 1016 diversity-is a significant barrier to entry for competitors and a foundation for developing targeted therapies.

Addressing significant unmet medical needs in cancer and pain

The company's pipeline is explicitly structured around high-need areas. In the immuno-oncology segment alone, the pipeline includes 37 programs targeting Neoplasms (cancers). The pain management focus, with RTX, targets patients with intractable pain who are opioid tolerant, defined in one study as consuming over 30 mg oral morphine equivalent dose daily. The value proposition is the potential to replace or significantly reduce reliance on existing, often problematic, standard-of-care treatments.

Here's a quick look at the pipeline focus:

• Neoplasms programs: 37
• Infectious Diseases programs: 18
• Top 5 Drug Types: ADC accounts for 15 programs
• RTX 20mcg dose showed durability past 26 weeks

The breadth of modalities-from small molecules (11 programs) to ADCs (15 programs) and Cell Therapy (8 programs)-shows a multi-pronged approach to tackling complex diseases. Despite the recent financial restructuring, including a Post IPO funding round of $47.4M on April 04, 2025, the scientific output remains the key value driver.

Value Proposition Area	Key Metric/Data Point	Associated Program/Technology
Non-Opioid Pain	20mcg dose outperformed steroid up to 26 weeks	RTX (Resiniferatoxin)
Immuno-Oncology	Library diversity of over 1016	G-MAB™ Antibody Library
Immuno-Oncology	Objective Response Rate of 30 percent in Phase 1b	IMC-002 (CD47 mAb) + Lenvima
Antiviral Therapy	Shortened COVID-19 recovery by 2.4 days vs. placebo	Ovydso (Olgotrelvir)
Platform Capability	15 programs classified as Antibody Drug Conjugate (ADC)	ADC Technology

Finance: draft 13-week cash view by Friday.

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Customer Relationships

You're looking at how Sorrento Therapeutics, Inc. (SRNE) manages its crucial relationships with the various stakeholders that drive its drug development and commercialization efforts as of late 2025. This isn't about selling widgets; it's about deep, often regulated, partnerships.

Collaborative relationships with principal investigators and clinical sites

The core of advancing the pipeline rests on these scientific relationships. You need top-tier investigators to run your trials effectively, especially with complex assets like CAR-T therapies. While the most recent specific operational data points to earlier engagement levels, these relationships are foundational to any near-term commercial success.

Here's a snapshot of the scale of collaboration that was in place, which informs the current relationship strategy:

Relationship Metric	Value	Date/Context
Active Cancer Centers Collaborating	87	As of 2023
Collaborative Networks Engaged	23	As of 2023
Ongoing Clinical Trials (Targeting Patient Needs)	5	As of 2023
Potential Collaboration Value (Pharma Partnerships)	Up to $127.6 million	Targeted as of 2023

These relationships are maintained through continuous research investment and a focus on patient-centric trial design, which is a major industry theme heading into 2025. If onboarding for new sites takes longer than expected, it definitely impacts trial timelines, a known risk for biotechs with leaner cash reserves.

High-touch engagement with regulatory bodies (FDA, EMA)

Engagement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is non-negotiable and requires a highly specialized, high-touch approach. This is about navigating complex submissions and responding to feedback on novel modalities like antibody-drug conjugates (ADCs) and cell therapies.

The regulatory landscape itself is evolving, with the EMA's Regulatory Science Strategy to 2025 emphasizing the need for better clinical trial methodologies. For Sorrento Therapeutics, Inc., past interactions set the stage; for instance, one key trial (NCT04572776) had a required reporting date of March 30, 2024, highlighting the strict timelines involved. The company's commercial product ZTlido® received its FDA approval on February 28, 2018, showing prior successful navigation of the approval process.

• Focus on providing data for cross-product meta-analyses to support scientific advice.
• Utilizing EMA Innovation Task Force briefings for early-stage interaction.
• Maintaining electronic submission compliance for all required Interactive Data Files.

Direct sales/marketing teams for commercial-stage products (post-2025)

The structure here is segmented, with the Scilex segment focused on non-opioid pain management products. While the company is described as clinical and commercial-stage, the scale of the direct sales force is tied to the commercial success of products like ZTlido® and the non-opioid pain assets like SEMDEXA™. Post-reorganization, the focus is likely on lean, targeted commercialization efforts.

The most recent financial event tied to capital structure was the Post IPO funding round on April 04, 2025, raising $47.4M. This capital infusion directly impacts the ability to fund and scale any direct sales or marketing infrastructure needed for products moving toward or in the market.

Investor relations focused on transparency post-reorganization

Following significant corporate events, investor confidence hinges on clear, consistent communication. For Sorrento Therapeutics, Inc., this means detailing the progress of the two main segments: Immune-Oncology and Scilex. Transparency is key, especially given the volatility reflected in the market data as of late 2025.

The market perception, as of December 05, 2025, showed a stock price of $0.0037 and a market capitalization of 2.016M. This low valuation relative to historical figures underscores the need for investor relations to clearly articulate the path to value realization from the pipeline and commercial assets. The company's focus on its G-MAB library and CAR-T therapies must be clearly communicated to institutional investors who participated in the April 2025 funding.

Patient advocacy groups for clinical trial recruitment and support

Patient advocacy groups are essential partners in the current environment, helping to bridge the trust gap and improve recruitment for trials targeting smaller, specific patient populations. This relationship is about co-designing healthcare with patients, as industry experts noted for 2025. Sorrento Therapeutics, Inc., being a San Diego biotech, operates within a cluster where legacy patient advocacy engagement is common.

The commitment here is demonstrated by focusing on patient outcomes and ensuring trial designs are convenient for participants, not just sponsors. This patient-centric approach helps maintain the flow of participants needed for the ongoing development of their immuno-oncology and pain management pipelines.

Finance: review Q4 2025 cash burn against the $47.4M raised in April 2025 by next Tuesday.

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Channels

You're looking at how Sorrento Therapeutics, Inc. gets its value propositions to its customers, which is a mix of direct sales, partnerships, and scientific outreach, especially given its clinical-stage focus and the structure involving the Scilex segment.

Direct engagement with hospitals and specialized treatment centers

Direct engagement is crucial for any clinical-stage biopharma company, particularly for specialized oncology and pain treatments. This channel involves the sales force and medical science liaisons interacting directly with key opinion leaders and treating physicians at major cancer centers and pain clinics.

• The company operates through the Sorrento Therapeutics segment, focusing on cancer and infectious disease treatments.
• The Scilex segment is organized around non-opioid pain management operations, requiring direct engagement with pain specialists.

Pharmaceutical distributors and wholesalers for commercial products

For commercial products, like those managed by the Scilex segment, distribution relies on established third-party logistics and wholesale networks. This is the standard path for getting approved drugs onto pharmacy shelves and into patient hands.

The overall TTM revenue for Sorrento Therapeutics, Inc. as of December 2025 was reported at $64.27 Million USD. This revenue is generated from license revenues, product revenues, the sale of customized reagents, and contract manufacturing/other services.

Revenue Component Implication	Financial Data Point (TTM Dec 2025)
Product Revenues (Implied via Scilex)	Contributes to total TTM Revenue of $64.27 Million USD
Total TTM Revenue	$64.27 Million USD

Scientific publications and medical conferences for data dissemination

Disseminating clinical data is a primary channel for building credibility and driving future partnership or adoption interest. This is a non-revenue generating channel that supports the entire pipeline.

• The company leverages its proprietary G-MAB library and various modalities like CAR-T and ADCs.
• The global clinical trial investigative site network market size was projected to be $9.36 billion in 2025.
• The oncology segment accounted for a 34% market share in the clinical trial investigative site network market in 2024.

Licensing and co-development agreements with larger pharma partners

Partnerships are a key channel for advancing the pipeline and generating non-dilutive funding through upfront payments, milestones, and royalties. The revenue structure confirms this channel's importance.

Revenue recognition explicitly includes License Revenues. The total transaction price of contracts is allocated to performance obligations, which can be recognized over the license period.

Revenue Stream	Source of Revenue
License Revenues	Recorded as deferred revenue upon cash receipt, recognized over the license period
Milestone-related development fees	Partnering objective to generate returns from product candidates
Royalties	Partnering objective to generate returns from product candidates

Clinical trial networks for patient access

The ability to enroll patients efficiently through established clinical trial networks is a direct channel for advancing drug candidates through development phases. This is critical for pipeline progression.

One historical Phase 2 trial for RTX involved a total of 120 participants. The company continues to advance multiple product candidates, including anti-PD-1, anti-PD-L1, and ADCs.

Institutional investor sentiment, as of November 2025, showed 9 institutional owners filing forms, holding a total of 3,951,657 shares.

The stock traded at $0.0041 as of December 3, 2025, with a reported market capitalization around $1.9M.

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Sorrento Therapeutics, Inc. (SRNE) as of late 2025. Honestly, the landscape is defined by the company's Chapter 11 liquidation process, which started back in February 2023. This means the traditional customer segments are now viewed through the lens of asset disposition and claim resolution managed by a liquidating trustee. Still, understanding the intended segments is crucial for valuing the residual assets.

The core therapeutic focus, before the wind-down, targeted patients across three major areas: cancer, infectious disease, and pain. The company's pipeline included assets for multiple myeloma and amyloidosis. For instance, in infectious disease response, Sorrento Therapeutics invested $31.6 million in COVID-19 related programs during 2023.

Here's a breakdown of the historical and residual customer segments:

• Patients with cancer, intractable pain, and autoimmune disorders
• Oncologists and pain specialists prescribing novel therapies
• Global pharmaceutical companies seeking licensing or acquisition targets
• Government and public health organizations for infectious disease treatments
• Creditors and equity holders in the reorganized entity

The segment of oncologists and pain specialists was central to the development of assets like Resiniferatoxin for intractable cancer pain. The company previously targeted academic cancer centers, noting collaborations with 87 active cancer centers as of 2024.

For potential deal-making, Sorrento Therapeutics aimed to partner with approximately 42 pharmaceutical companies, with potential collaboration values estimated up to $127.6 million. This speaks to the value proposition once held for licensing partners.

The most immediate, post-restructuring 'customers' are the financial stakeholders. As of late 2025, the entity trades on the OTC Expert Market under SRNEQ. The company reported approximately $1 billion in assets at the time of its Chapter 11 filing, though the current market capitalization for the residual entity is small, around $2.3 million or $2.76 million.

The most concrete financial distribution involves the equity holders. Former Sorrento Therapeutics common shareholders received 7% equity in Vivasor, Inc., which acquired certain assets from Sorrento for a purchase price of $1.8 million in cash. This 7% stake represents the pro-rata distribution of value for those who were equity holders. To give you a sense of the prior operational scale, a comparison shows a Gross Revenue figure of $60.32 million, though this is against a backdrop of a Net Loss of -$572.84 million.

Here's a quick look at the segment scale and financial context based on available data, keeping in mind the company is in liquidation:

Customer Segment Focus Area	Relevant Metric/Value	Context/Date Reference
Infectious Disease Investment	$31.6 million	Investment in COVID-19 related programs in 2023
Potential Pharma Partnerships Value	$127.6 million	Potential collaboration value target
Vivasor Equity Stake for Shareholders	7%	Equity received by former SRNE common shareholders in Vivasor, Inc.
Vivasor Asset Purchase Price	$1.8 million	Cash paid for acquired assets by Vivasor, Inc.
Prior Gross Revenue (Segment Context)	$60.32 million	Reported Gross Revenue figure for comparison
Prior Asset Base at Filing	Approx. $1 billion	Reported assets at Chapter 11 filing
Institutional Ownership (Late 2025)	0.0%	Institutional investor ownership of SRNE shares

The segment of global pharmaceutical companies was historically important for leveraging the G-MAB antibody library and ADC technologies. The company also had a non-opioid pain management focus through its Scilex segment.

If onboarding takes 14+ days for any residual administrative processes managed by the trustee, claim resolution risk rises. Finance: draft 13-week cash view by Friday.

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Cost Structure

You're looking at the hard costs Sorrento Therapeutics, Inc. (SRNE) faces, especially while navigating the Chapter 11 process. These aren't projections; these are the actual financial drains we see from their filings and related proceedings.

Significant R&D expenses for clinical trials and preclinical research remain a core cost, even under bankruptcy protection. For instance, total research and development expenses for the three months ended March 31, 2022, totaled $\mathbf{\$63,977 \text{ thousand}}$ across the Sorrento and Scilex segments, with the Sorrento segment alone showing $\mathbf{\$61,346 \text{ thousand}}$ in R&D costs for that period. This reflects the ongoing, high-cost nature of advancing drug candidates through development pipelines.

The legal and professional fees from the Chapter 11 bankruptcy process have been substantial, leading to disputes among stakeholders. As of mid-2024, professional firms were seeking approximately $\mathbf{\$50 \text{ million}}$ in total fees related to the case.

Here's a breakdown of those significant professional fee requests:

• Latham & Watkins LLP: Seeking $\mathbf{\$27 \text{ million}}$
• M3 Advisory Partners LP: Seeking $\mathbf{\$12.4 \text{ million}}$
• Moelis & Company LLC: Requesting $\mathbf{\$7.5 \text{ million}}$
• Jackson Walker: Requesting $\mathbf{\$2.5 \text{ million}}$
• Tran Singh LLP: Seeking $\mathbf{\$137,400}$

The manufacturing and supply chain costs for drug production are inherent to any biopharma operation, though specific 2025 figures aren't immediately available outside of general Selling, General and Administrative (SG&A) components from earlier filings. We know SG&A expenses for the three months ended March 31, 2022, totaled $\mathbf{\$44,327 \text{ thousand}}$.

Salaries and benefits for specialized scientific and clinical staff are embedded within the R&D and SG&A figures, as R&D expenses specifically include salaries and personnel-related expenses. The increase in R&D expenses in early 2022 was driven by higher headcount, showing this is a persistent cost driver.

Regarding interest expense on outstanding debt, including the $\mathbf{\$100 \text{ million}}$ Oramed loan, the structure involves significant debt service obligations. Sorrento Therapeutics, Inc. secured a $\mathbf{\$100,000,000}$ Replacement DIP Facility from Oramed Pharmaceuticals Inc. in August 2023. This facility, which replaced an earlier JMB DIP Facility, had an interest rate per annum equal to SOFR plus $\mathbf{8.5\%}$. The resulting Senior Secured Promissory Note, assumed by Scilex, was set to mature on March 21, 2025, with principal repayment installments beginning in late 2023.

Here's a summary of the key debt/financing components that drive interest costs:

Financing Instrument	Principal Amount	Key Date/Rate Detail
Oramed Replacement DIP Facility	$\mathbf{\$100,000,000}$	Interest: SOFR plus $\mathbf{8.5\%}$
JMB DIP Facility (Refinanced)	$\mathbf{\$75,000,000}$	Matured July 31, 2023
Oramed Note Maturity Date	N/A	March 21, 2025

Finance: draft 13-week cash view by Friday.

Sorrento Therapeutics, Inc. (SRNE) - Canvas Business Model: Revenue Streams

You're looking at how Sorrento Therapeutics, Inc. plans to bring in cash as of late 2025, which is critical given the recent restructuring. The revenue picture is a mix of projections, asset monetization, and financing activities.

The primary forward-looking metric available suggests a significant jump from prior years' actuals. Analysts are projecting the following for the current period:

• Forecasted annual revenue for the 2025 fiscal year is set at $416 million.

The company's historical revenue figures give you context for that projection, with 2022 revenue at $62.84 Million USD and 2023 (TTM) revenue at $64.27 Million USD.

One major component of recent cash generation involved divesting non-core assets, specifically the stake in Scilex Holding Company. This was a key part of the post-bankruptcy strategy.

Asset Sale Component	Financial Amount (USD)
Stalking Horse Bid for Scilex Securities	$105 million
Aggregate Consideration in Consummated Sale (Sept 2023)	$110 million
Assumption of Oramed Pharmaceuticals DIP Loan by Scilex	Approximately $100 million
Assumption of Sorrento Legal Fees by Scilex	Approximately $12.25 million

While the Scilex transaction is largely concluded, past milestone receipts provide a template for future non-sales revenue. For example, Sorrento recuperated $125 million from NantPharma for unmet milestones. Specific, confirmed milestone payments from new licensing and collaboration agreements executed in 2025 aren't detailed in the latest available data, but the structure of pharma deals suggests this stream relies on hitting specific regulatory or sales targets for pipeline assets.

To fund ongoing operations, especially through the development pipeline, Sorrento Therapeutics has tapped capital markets. You need to track these infusions as they directly impact the cash runway.

• A recent equity financing round, described as a Post IPO event, closed on April 4, 2025, raising $47.4 million.
• Earlier, in March 2024, the company obtained a senior secured term loan facility of $5 million as part of its Debtor-in-Possession (DIP) financing to support the bankruptcy emergence process.

As for potential product sales from commercialized assets post-2025, that revenue stream is entirely contingent on successful clinical progression and regulatory approval for their pipeline candidates, such as the anti-CD47 therapies. No specific sales forecasts post-2025 are available to quantify this stream yet. Finance: draft 13-week cash view by Friday.